ALDERIA INTELLIGENCE
← All signals
PubMed1 Apr 2026Obesity reviews : an official journal of the International Association for the Study of Obesity● 3/10i

Comparative Efficacy of Different Exercise Interventions on Intrahepatic Lipid Content, Glucose Homeostasis, and Liver Function in Adults With and Without Nonalcoholic Fatty Liver Disease: A Systematic Review With Pairwise and Network Meta-Analyses.

Khalafi M, Fatolahi S, Symonds ME, Rosenkranz SK, Dinizadeh F et al.

High-intensity interval training reduced intrahepatic lipid content most effectively (p-score 0.95), followed by aerobic training (0.77), combined training (0.52), and resistance training (0.10) in adults with and without NAFLD. Network meta-analysis of 38 studies with 1,880 participants comparing exercise interventions. This provides the first head-to-head comparison ranking different exercise modalities for liver fat reduction, filling a critical evidence gap for clinical guidelines and treatment algorithms. Exercise also reduced fasting glucose, insulin, HbA1c, and liver enzymes ALT/AST compared to no exercise.

Strategic Signal

This systematic review reinforces exercise as first-line NAFLD treatment, potentially strengthening payer resistance to expensive NAFLD therapies like Madrigal's resmetirom in US and EU markets. Health technology assessment bodies will likely reference this data to justify stepped care approaches requiring lifestyle modification failures before drug coverage. The evidence supports current clinical guidelines positioning exercise before pharmaceutical intervention, creating higher reimbursement barriers for emerging NAFLD treatments.

Liver/NASH

Original Abstract

OBJECTIVES: This study investigated the effects of different exercise interventions on intrahepatic lipid content and markers of glucose homeostasis and liver function in adults with and without nonalcoholic fatty liver disease (NAFLD). METHODS: A comprehensive search was conducted in PubMed, Scopus, Web of Science, and EMBASE using three primary keywords including "exercise training," "liver fat," and "randomization" from inception to August 2025. Eligible studies were those that compared exercise training with either nonexercise groups or other types of exercise training. RESULTS: Thirty-eight studies comprising 1880 participants were included. Exercise training was more effective for reducing intrahepatic lipids [SMD: -0.33, p = 0.001], confirmed through subgroup analyses based on age, health status, body mass index, intervention duration, specific health status, frequency of weekly exercise sessions, biological sex, steatosis classification, and weight change%. Based on the p-score rankings, the intervention that was likely to be the most effective for lowering intrahepatic lipids was high-intensity interval training (p = 0.95), followed by aerobic training (p = 0.77), combined aerobic and resistance training (p = 0.52), and resistance training (p = 0.10). Secondarily, exercise training reduced fasting blood glucose [WMD: -2.27 mg/dL, p = 0.007], fasting insulin [SMD: -0.16, p = 0.02], glycated hemoglobin [SMD: -0.13, p = 0.03], and liver function enzymes including alanine aminotransferase (ALT) [WMD: -3.72 U/L, p = 0.001] and aspartate aminotransferase (AST) [WMD: -3.51 U/L, p = 0.02] significantly more than nonexercise groups. However, there were no significant differences in insulin resistance. CONCLUSIONS: These results provide evidence of the effects of different exercise interventions as part of a healthy lifestyle for reducing intrahepatic lipids and markers of glucose dysmetabolism. PROSPERO Registration: CRD42025639421.

Related signals

Strategic Signal

Clinical Trial16 Apr 2026Phase 3● 7/10i

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

Boehringer Ingelheim is testing survodutide, a once-weekly injectable, in people with compensated NASH/MASH cirrhosis in a phase 3 trial targeting liver-related clinical outcomes. The randomized, placebo-controlled study aims to enroll 1,590 participants over 4.5 years, measuring time to death, liver transplant, hepatic decompensation, or disease progression. This represents Boehringer's entry into the competitive NASH space where Novo Nordisk's semaglutide is already in phase 3 trials for non-cirrhotic NASH. The trial focuses on advanced cirrhotic patients, a population with high unmet need but challenging regulatory pathway.

Strategic Signal

PubMed21 Apr 2026Diabetologia● 6/10i

Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease.

Adults with early-stage metabolic dysfunction-associated steatotic liver disease (MASLD) absorbed 52% more glucose during oral tolerance testing compared with matched controls, with enhanced glucose absorption showing fivefold higher odds of MASLD independent of confounders. Study used stable isotope methodology in two separate cohorts measuring glucose kinetics and gastric emptying during 75g oral glucose tolerance tests. This identifies intestinal glucose absorption as a potential early driver of liver disease that precedes hepatic insulin resistance, suggesting a new therapeutic target upstream of existing MASLD interventions. The enhanced absorption occurred independently of gastric emptying rate, pointing to intestinal-specific mechanisms.

Liver/NASHType 2 diabetesMechanisms

Strategic Signal

PubMed14 Apr 2026Cell metabolism● 6/10i

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Semaglutide improved liver fibrosis, steatosis, and inflammation in mice with MASH through weight-loss-independent mechanisms targeting GLP-1 receptors on liver sinusoidal endothelial cells. Preclinical study using genetically modified mouse models with targeted GLP-1 receptor deletions and transcriptomic profiling. This identifies a novel hepatic mechanism for GLP-1 receptor agonists that could support liver indication development beyond weight loss effects. Study limited to mouse models without human validation.

GLP-1Liver/NASHMechanismsNovo Nordisk

Strategic Signal

PubMed13 Apr 2026Diabetes, obesity & metabolism● 6/10i

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.

Semaglutide showed no association with reduced risk of liver cirrhosis (HR 1.3, 95% CI 0.98-1.77) or hepatocellular carcinoma (HR 0.6, 95% CI 0.21-1.51) in adults with type 2 diabetes. Retrospective cohort study of 71,612 patients with median follow-up exceeding 4,000 days. This contradicts emerging hypotheses about GLP-1 receptor agonists providing liver protection beyond metabolic benefits, suggesting hepatic outcomes may not become a differentiated messaging opportunity.

GLP-1Type 2 diabetesLiver/NASHNovo Nordisk

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.

Questions? Book a consultation →